ASND - Ascendis Pharma AS - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ASND is currently covered by 15 analysts with an average price target of $216.94. This is a potential upside of $59.4 (37.7%) from yesterday's end of day stock price of $157.54.

Ascendis Pharma AS's activity chart (see below) currently has 222 price targets and 211 ratings on display. The stock rating distribution of ASND is 83.13% BUY and 16.87% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 48.68% with an average time for these price targets to be met of 323.48 days.

Highest price target for ASND is $289, Lowest price target is $153, average price target is $204.53.

Most recent stock forecast was given by VIKRAM PUROHIT from MORGAN STANLEY on 05-May-2025. First documented stock forecast 22-Feb-2015.

Currently out of the existing stock ratings of ASND, 69 are a BUY (83.13%), 14 are a HOLD (16.87%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$250

$98.75 (65.29%)

$167

11 days ago
(05-May-2025)

19/21 (90.48%)

$79.26 (46.42%)

221

Buy

$245

$93.75 (61.98%)

$200

14 days ago
(02-May-2025)

19/23 (82.61%)

$72.94 (42.39%)

145

Buy

$280

$128.75 (85.12%)

$260

14 days ago
(02-May-2025)

3/10 (30%)

$107.94 (62.73%)

686

Buy

$200

$48.75 (32.23%)

$170

2 months 21 days ago
(24-Feb-2025)

10/18 (55.56%)

$48.47 (31.99%)

199

Buy

$194

$42.75 (28.26%)

$179

5 months ago
(15-Dec-2024)

1/4 (25%)

$57.4 (42.02%)

477

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ASND (Ascendis Pharma AS) average time for price targets to be met?

On average it took 323.48 days on average for the stock forecasts to be realized with a an average price target met ratio 48.68

Which analyst has the current highest performing score on ASND (Ascendis Pharma AS) with a proven track record?

JOSH SCHIMMER

Which analyst has the most public recommendations on ASND (Ascendis Pharma AS)?

Josh Schimmer works at EVERCORE and has 3 price targets and 2 ratings on ASND

Which analyst is the currently most bullish on ASND (Ascendis Pharma AS)?

Derek Archila with highest potential upside - $137.75

Which analyst is the currently most reserved on ASND (Ascendis Pharma AS)?

Tiago Fauth with lowest potential downside - -$62.25

Ascendis Pharma AS in the News

Ascendis Pharma AS (ASND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

Total Revenue: EUR101 million for the first quarter. YORVIPATH Revenue: EUR44.7 million in Q1, up from EUR13.6 million in Q4 2024. SKYTROFA Revenue: EUR51.3 million for the quarter. R&D Expenses: EUR86.6 million in Q1 2025, compared to EUR70.7 million in Q1 2024. SG&A Expenses: EUR101 million in Q1 2025, up from EUR66.8 million in Q1...

Ascendis Pharma Reports First Quarter 2025 Financial Results

– Q1 2025 revenue of €44.7 million for YORVIPATH® and €51.3 million for SKYTROFA® – TransCon™ CNP NDA submitted in Q1 2025; MAA submission planned in Q3 2025 – Topline COACH combination trial (TransCon CNP + TransCon hGH)data expected in Q2 2025 – Conference call today at 4:30 pm ET COPENHAGEN, Denmark, May 01, 2025...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?